CONGRESS SNAPSHOTscientificsecretariat.com/menarini/2016/ESC_Rome/Ranexa/...of stable angina...
2
As every year, the Menarini Group was present at the European Society of Cardiology (ESC) congress, which - with more than 33,000 participants from all over the world, is the largest and most influential European meeting in the field of cardiology. During the ESC congress, held in Rome (IT) from 27 th to 31 st August 2016, the Menarini Group sponsored the satellite symposium “New approaches to stable coronary artery disease (SCAD): broadening the management paradigm”, which took place on 28 th August. The scope of the symposium, which was co-chaired by Professors A.J. Camm (UK) and J.L. López-Sendón (ES), was to provide practical insights for implementing a patient-tailored approach in the management of stable angina pectoris. Prof. G. Ambrosio (IT) kicked off the symposium with a provocative lecture centered on the unmet needs in the management of patients with SCAD and angina. Symptomatic angina is often underappreciated, and a large proportion of patients remain symptomatic despite successful revascularization. Furthermore, some patients have microvascular angina, which may be responsible for the persistence of symptoms after revascularization. Lack of consensus on the “optimal medical therapy” to be used and discrepancy between actual disease severity and judgment of clinical conditions by physicians represent further hurdles to effective SCAD management. During the second lecture, prof. A.J. Manolis (GR) presented a recently published algorithm 1 for the management of SCAD. After reviewing each class of antianginal medication, he concluded that beta-blockers, calcium channel blockers, ranolazine and ivabradine could all be used as initial therapy, and that the choice of drug should be based on patient’s characteristics, i.e. haemodynamic status and comorbidities. Of note, the antianginal agent ranolazine, which has a haemodynamycally neutral mechanism of action, could be used in most clinical situations. The third session was in the form of an interactive discussion of representative clinical cases, which were illustrated by Priv. Doz. R. Dechend (DE). He described three relatively common clinical situations – a man with diabetes who complained of angina despite successful revascularization Chairmen: A. J. Camm (UK) and J. L. Lopez-Sendon (ES) CONGRESS SNAPSHOT Room Paris Village 7 28 th AUGUST 2016 Sunday 18.30 - 20.00 NEW APPROACHES TO STABLE CORONARY ARTERY DISEASE (SCAD): BROADENING THE MANAGEMENT PARADIGM A . J . C a m m ( U K ) J . L . L o p e z - S e n d o n ( E S ) SATELLITE SYMPOSIUM
Transcript of CONGRESS SNAPSHOTscientificsecretariat.com/menarini/2016/ESC_Rome/Ranexa/...of stable angina...
-
As every year, the Menarini Group was present at the European Society of Cardiology (ESC) congress, which - with more than 33,000 participants from all over the world, is the largest and most influential European meeting in the field of cardiology.During the ESC congress, held in Rome (IT) from 27th to 31st August 2016, the Menarini Group sponsored the satellite symposium “New approaches to stable coronary artery disease (SCAD): broadening the management paradigm”, which took place on 28th August. The scope of the symposium, which was co-chaired by Professors A.J. Camm (UK) and J.L. López-Sendón (ES), was to provide practical insights for implementing a patient-tailored approach in the management of stable angina pectoris. Prof. G. Ambrosio (IT) kicked off the symposium with a provocative lecture centered on the unmet needs in the management of patients with SCAD and angina. Symptomatic angina is often underappreciated, and a large proportion of patients remain symptomatic despite successful revascularization. Furthermore, some patients have microvascular angina, which may be responsible for the persistence of symptoms after revascularization. Lack of consensus on the “optimal medical therapy” to be used and discrepancy between actual disease severity and judgment of clinical conditions by physicians represent further hurdles to effective SCAD management. During the second lecture, prof. A.J. Manolis (GR) presented a recently published algorithm1 for the management of SCAD. After reviewing each class of antianginal medication, he concluded that beta-blockers, calcium channel blockers, ranolazine and ivabradine could all be used as initial therapy, and that the choice of drug should be based on patient’s characteristics, i.e. haemodynamic status and comorbidities. Of note, the antianginal agent ranolazine, which has a haemodynamycally neutral mechanism of action, could be used in most clinical situations.The third session was in the form of an interactive discussion of representative clinical cases, which were illustrated by Priv. Doz. R. Dechend (DE). He described three relatively common clinical situations – a man with diabetes who complained of angina despite successful revascularization
Chairmen: A. J. Camm (UK) and J. L. Lopez-Sendon (ES)
CONGRESS SNAPSHOT
Room ParisVillage 7
28th AUGUST 2016Sunday
18.30 - 20.00
NEW APPROACHES TO STABLE CORONARY ARTERY DISEASE (SCAD): BROADENING THE MANAGEMENT PARADIGM
A. J. Camm (UK)
J. L. Lopez-Sendon (E
S)
SATELLITE SYMPOSIUM
-
few months earlier, a woman with microvascular angina and an elderly man who could not tolerate guideline-recommended first line antianginal drugs due to low blood pressure and heart rate. During the session, a remote voting system allowed participants to give their opinion about key decisions on the management of each patient, thus providing the panel of experts with prompts for an insightful discussion on both diagnostic and therapeutic choices. The symposium met with excellent response, featuring nearly 800 attendees.
1 Manolis AJ, et al. Medical treatment of stable angina: A tailored therapeutic approach. Int J Cardiol. 2016 Oct 1;220:445-53.
FOR INTERNAL USE ONLY
MCI-293-1604
Photo of the room Paris
NEW APPROACHES TO STABLE CORONARY ARTERY DISEASE (SCAD): BROADENING THE MANAGEMENT PARADIGM
SATELLITE SYMPOSIUM
